GAS5 and non-small cell lung carcinoma: In our study, the expression of GAS5-downstream molecules in type I interferon signaling was higher in patients who were able to achieve DCB than in patients who could not achieve DCB, indicating that the downregulation of GAS5 in NSCLC might be correlated with worse prognosis in NSCLC patients receiving anti-PD-1/anti-PD-L1 treatment.